Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
Vir Biotechnology, Inc. (VIR) will be participating in key investor conferences in March, with Marianne De Backer, CEO, engaging in fireside chats and one-on-one meetings. The events aim to enhance investor relations and showcase the company's progress.
02/23/2024 - 08:05 AM
SAN FRANCISCO --(BUSINESS WIRE)--
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March:
TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston . Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Monday, March 4, at 2:50 p.m. ET / 11:50 a.m. PT.
Leerink Partners Global Biopharma Conference at the Fontainebleau Hotel in Miami Beach . Vir management will be hosting one-on-one investor meetings on Monday, March 11 and Tuesday, March 12.
Barclays 26th Annual Global Healthcare Conference at Loews Miami Beach Hotel in Miami . Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, March 12, at 7:30 a.m. ET / 4:30 a.m. PT.
Live webcasts of the fireside chats can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220184688/en/
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1-314-368-5189
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
+1 978-973-9986
Source: Vir Biotechnology, Inc.
When is Marianne De Backer scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference?
Marianne De Backer is scheduled to participate in a fireside chat on Monday, March 4, at 2:50 p.m. ET / 11:50 a.m. PT.
Where will Vir management be hosting one-on-one investor meetings during the Leerink Partners Global Biopharma Conference?
Vir management will be hosting one-on-one investor meetings at the Fontainebleau Hotel in Miami Beach on Monday, March 11 and Tuesday, March 12.
How long will the live webcasts of the fireside chats be accessible on the Vir website?
The live webcasts of the fireside chats can be accessed on the Vir website at www.vir.bio under Events & Presentations and will be archived for 30 days.
Vir Biotechnology Inc
NASDAQ:VIR
VIR Rankings
#5021 Ranked by Stock Gains
VIR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Commercial Services, Miscellaneous Commercial Services, Health Technology, Biotechnology
About VIR
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.